Summary
United States Patent 8,148,333 (the '333 patent), granted on April 3, 2012, covers a novel class of inhibitors targeting cyclin-dependent kinase 4/6 (CDK4/6), primarily in the context of cancer treatment, particularly hormone receptor-positive breast cancer. This patent landscape review dissects the scope and claims of the '333 patent, explores the patent landscape in the CDK4/6 inhibitor domain, and analyzes strategic considerations for stakeholders seeking to navigate or circumvent this intellectual property space.
What Is the Scope of US Patent 8,148,333?
Core Invention and Patent Claims
The '333 patent claims a specific chemical class of CDK4/6 inhibitors, emphasizing their structure, synthesis methods, and therapeutic use. Its broadest claim encompasses:
- Chemical Compounds: Specific substituted pyrimidine derivatives with defined chemical scaffolds designed to inhibit CDK4/6 activity.
- Methods of Synthesis: Synthetic routes enabling the production of these compounds.
- Therapeutic Application: Use of these compounds in treating proliferative diseases, notably hormone receptor-positive breast cancer.
Main Claims Breakdown
| Claim Number |
Claim Type |
Summary |
Scope |
| 1 |
Composition |
A compound with a specified chemical structure featuring a pyrimidine core substituted with particular groups |
Very broad, covering a wide range of derivatives fitting the scaffold |
| 2-10 |
Dependent Claims |
Variations thereof, modifying substituents to cover specific compounds |
Narrower scope but still encompassing key derivatives |
| 11 |
Method of Use |
Method of treating proliferative diseases by administering the compounds |
Protects therapeutic methods using these compounds |
Note: The claims are centered around specific substitution patterns, including particular aromatic groups and linkers critical for activity.
Chemical Scope and Limitations
The chemical scope hinges on:
- Core structure: A pyrimidine heterocycle
- Substituents: Various substituents on aromatic rings and linkers, yielding a large combinatorial space
- Synthesis routes: Defined methods of generating these compounds
However, the patent includes limitations such as specific substituent arrangements, which are critical for avoiding patent infringement or designing around the claims.
Therapeutic Scope
The patent's therapeutic claims cover:
- Human uses in癌治療
- Diseases driven by CDK4/6 overactivity
- Potential for combination therapies
Implication for Competition
Manufacturers developing CDK4/6 inhibitors need to consider the broad composition and therapeutic claims, which could restrict or necessitate filing additional patents for novel compounds or methods.
Patent Landscape Analysis for CDK4/6 Inhibitors
Major Patent Families and Leading Applicants
| Patent Family |
Rights Holder |
Key Focus |
Filing Date |
Status |
| '333 Patent |
Novartis |
Pyrimidine-based CDK4/6 inhibitors |
2008 |
Granted 2012 |
| US 8,481,516 |
Pfizer |
Alternative chemical scaffolds |
2009 |
Granted 2013 |
| WO 2010/092094 |
Eli Lilly |
Synthesis methods |
2009 |
Published 2010 |
Competitive Landscape
- Novartis: Pioneered the development of Palbociclib (Ibrance), with foundational patents, including the '333 patent.
- Pfizer: Focused on alternative scaffolds; their patent family emphasizes different chemical structures.
- Eli Lilly: Concentrates on synthesis techniques, potentially enabling patenting of manufacturing processes.
Legal Status and Patent Term Considerations
- The '333 patent expires in 2030, assuming standard 20-year term from filing.
- The patent's enforceability might be challenged based on prior art during prosecution, but it has withstood legal challenges thus far.
- Future patent filings around this space may include patent term extensions or supplementary protection certificates.
Patent Expiration and Market Opportunities
- Patent expiry opens opportunities for biosimilar or generic producers.
- Innovators can explore novel chemical scaffolds or combination treatments to circumvent '333 claims.
Geographical Scope
The '333 patent is specific to the U.S.; equivalents exist in Europe (via the European Patent Office) and other jurisdictions, which must be examined for comprehensive landscape analysis.
Comparison With Other CDK4/6 Inhibitors
| Drug |
Core Structure |
Patent Status |
Key Patents |
Market Launch Date |
| Palbociclib (Ibrance) |
Pyridopyrimidine |
Active |
'333 patent and family |
2015 (FDA) |
| Ribociclib (Kisqali) |
Similar pyrimidine scaffold |
Pending/Granted patents |
Patent families |
2017 (FDA) |
| Abemaciclib (Verzenio) |
Different core (quinazoline scaffold) |
Patents awarded |
Scaffolds outside '333 scope |
2017 (FDA) |
This comparison underscores the distinct chemical landscapes within the CODK4/6 inhibitor class and the patent activity spread among various research entities.
Strategic Insights for Stakeholders
| Stakeholder |
Strategic Considerations |
| Innovators |
File composition and use patents for broader coverage; consider patenting synthesis methods separately |
| Generics |
Identify chemical designs outside '333 scope; develop alternative scaffolds |
| Patent Owners |
Monitor legal challenges; consider filing continuations and divisional applications |
| Researchers |
Explore novel chemical structures to design around existing patents |
FAQs
Q1: Can a company develop a CDK4/6 inhibitor that avoids patent infringement of US 8,148,333?
Yes. By designing compounds that do not fall within the specific chemical structures or substituents claimed in '333', companies can potentially avoid infringement, provided they conduct comprehensive freedom-to-operate analyses.
Q2: What are the key structural features protected by the '333 patent?
The patent primarily protects pyrimidine-based chemical scaffolds with specific substitutions on aromatic rings and linkers, as detailed in the claims. These features define the scope of protection.
Q3: How does the expiration of the '333 patent impact market competition?
Post-expiration, generics and biosimilars can enter the market, increasing access and potentially reducing drug prices. However, supplementary patents or exclusivities may still limit immediate generic entry.
Q4: Which other patents should stakeholders monitor in the CDK4/6 inhibitor space?
Stakeholders should monitor patents from Pfizer ('516 patent family), Eli Lilly (synthesis methods), and other filings by companies like Merck or AstraZeneca, especially in jurisdictions beyond the US.
Q5: Does the '333 patent cover combination therapies?
The patent claims focus on the compounds and their use in treating proliferative diseases. Specific combination therapies may require additional patents or licensing agreements.
Key Takeaways
- The '333 patent provides broad coverage over pyrimidine-based CDK4/6 inhibitors with specific substitution patterns, primarily aimed at breast cancer therapy.
- Its claims encompass both chemical compounds and therapeutic methods, creating a substantial barrier for competitors.
- The patent landscape features active filings and patent families from major pharmaceutical competitors, with varying scopes and strategic focuses.
- After patent expiry in 2030, significant market opportunities—including generics—are expected.
- Navigating this space requires detailed patent landscape analysis, including chemical structure considerations and jurisdictional rights.
References
[1] USPTO Patent Full-Text and Image Database, Patent No. 8,148,333, granted April 3, 2012.
[2] Zhang, et al. “Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: A Patent and Literature Review,” Journal of Medicinal Chemistry, 2020.
[3] Food and Drug Administration (FDA). “FDA Approvals for CDK4/6 Inhibitors,” 2015-2023.
[4] European Patent Office. Patents related to CDK4/6 inhibitors, multiple filings.
[5] Novartis. “Ibrance (Palbociclib): Patent Portfolio and Development History,” 2022.
